

Claim Amendments:

Claim 1 (Cancelled)

Claim 2. (Currently amended): A method ~~according to claim 1~~ for the treatment of obesity which comprises administering to a patient in need of such treatment an effective amount of a reversible mixed inhibitor of monoamine oxidase A and B.

Claim 3. (Previously amended): A method according to claim 2 wherein the reversible mixed inhibitor of monoamine oxidase A and B is chosen from [3(*S*),3a(*S*)]-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1*H*-oxazolo[3,4-*a*]quinolin-1-one, (*R*)-5-(methoxymethyl)-3-[6-(4,4,4-trifluorobutoxy)benzofuran-3-yl]oxazolidin-2-one and (*R*)-5-(methoxymethyl-3-(6-cyclopropyl-methoxybenzofuran-3-yl)oxazolidin-2-one.

Claim 4. (Currently amended): A method ~~according to claim 1~~ for the treatment of obesity which comprises administering to a patient in need of such treatment an effective amount of a reversible selective inhibitor of monoamine oxidase B.

Claim 5 (Cancelled)

Claim 6. (Previously amended): A method according to claim 4 wherein the reversible selective inhibitor of monoamine oxidase B is (*S*)-5-(methoxymethyl)-3-[6-(4,4,4-trifluorobutoxy)-1,2-benzisoxazol-3-yl]oxazolidin-2-one.

Claims 7-8 (Cancelled)

Claim 9. (Currently amended) A method ~~according to claim 8 wherein the reversible selective inhibitor of monoamine oxidase A is~~ for the treatment of obesity which comprises administering to a patient in need of such treatment an effective amount of befloxatone.

Claim 10. (Previously amended): A method according to claim 9 wherein the dosage amount of befloxatone is from about 2.5 to 40 mg per day.

Claim 11. (Previously amended): A method according to claim 10 wherein the amount of befloxatome is from about 10 to 20 mg.

Claims 12-13 (Cancelled)

Claim 14. (Currently amended): A method ~~according to claim 13~~ for the treatment of obesity which comprises administering to a patient in need of such treatment an effective amount of a reversible mixed inhibitor of monoamine oxidase A and B.

Claim 15. (Previously added): A method according to claim 14 wherein the reversible mixed inhibitor of monoamine oxidase A and B is chosen from [3(S),3a(S)]-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1*H*-oxazolo[3,4-*a*]quinolin-1-one, (*R*)-5-(methoxymethyl)-3-[6-(4,4,4-trifluorobutoxy)benzofuran-3-yl]oxazolidin-2-one and (*R*)-5-(methoxymethyl-3-(6-cyclopropyl-methoxybenzofuran-3-yl)oxazolidin-2-one.

Claim 16. (Currently amended): A method ~~according to claim 13~~ for the treatment of obesity which comprises administering to a patient in need of such treatment an effective amount of a reversible selective inhibitor of monoamine oxidase B.

Claim 17 (Cancelled)

Claim 18. (Previously added): A method according to claim 16 wherein the reversible selective inhibitor of monoamine oxidase B is (*S*)-5-(methoxymethyl)-3-[6-(4,4,4-trifluorobutoxy)-1,2-benzisoxazol-3-yl]oxazolidin-2-one.

Claims 19-20 (Cancelled)

Claim 21. (Currently amended): A method ~~according to claim 20~~ wherein the reversible selective inhibitor of monoamine oxidase A is for the treatment of obesity which comprises administering to a patient in need of such treatment an effective amount of befloxatone.

Claim 22. (Previously added): A method according to claim 21 wherein the dosage amount of befloxtone is from about 2.5 to 40 mg per day.

Claim 23. (Previously added): A method according to claim 22 wherein the amount of befloxtome is from about 10 to 20 mg.